NBIX Stock: Price, Earnings History and SEC Filings
Neurocrine Biosciences, Inc. (NBIX) last traded at $146.10, down 0.19% on the latest session and up 3.0% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $2.36 against an analyst estimate of $1.88, a beat of 25.5%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
NBIX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 30, 2026 | $2.36 | $1.88 | +25.53% |
| Mar 2026 | May 5, 2026 | $1.41 | $1.28 | +10.16% |
| Dec 2025 | Feb 11, 2026 | $1.43 | $1.78 | -19.66% |
| Sep 2025 | Oct 28, 2025 | $2.04 | $1.58 | +29.11% |
NBIX beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How NBIX reacts to earnings
Across its last 8 earnings releases, NBIX moved 9.5% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-07-30 | After close | -10.08% |
| 2026-05-05 | After close | +8.86% |
| 2026-02-11 | After close | -10.43% |
| 2025-10-28 | After close | -6.35% |
| 2025-07-30 | After close | -6.24% |
| 2025-05-05 | After close | +8.36% |
| 2025-02-06 | After close | -18.53% |
| 2024-10-30 | Before open | +7.01% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
NBIX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $2.9B | $479M | $749M | 16.7% | $4.67 |
| 2024 | $2.4B | $341M | $557M | 14.5% | $3.29 |
| 2023 | $1.9B | $250M | $362M | 13.2% | $2.47 |
| 2022 | $1.5B | $155M | $323M | 10.4% | $1.56 |
| 2021 | $1.1B | $90M | $233M | 7.9% | $0.92 |
| 2020 | $1.0B | $407M | $218M | 38.9% | $4.16 |
| 2019 | $788M | $37M | $132M | 4.7% | $0.39 |
| 2018 | $451M | $21M | $77M | 4.7% | $0.22 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for NBIX
- 8-K · Sep 28, 2026Officer or director change
- 10-Q · Jul 31, 2026
- 8-K · Jul 30, 2026Results of operations, Financial statements and exhibits
- 8-K · May 28, 2026Officer or director change, Shareholder vote
- 8-K · May 18, 2026Material agreement, Acquisition or disposal completed, New financial obligation
- 10-Q · May 5, 2026
- 8-K · May 5, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 15, 2026
- 8-K · Apr 6, 2026Material agreement, Financial statements and exhibits
- 10-K · Feb 11, 2026
Insider filing activity
NBIX insiders filed 13 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
NBIX news
- Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal HyperplasiaOct 30, 2026 · finance.yahoo.com
- Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter 2026Oct 30, 2026 · finance.yahoo.com
- Here's why Neurocrine Biosciences (NBIX) is a strong growth stockOct 30, 2026 · msn.com
- Neurocrine Biosciences stock: Q3 results set for November 2Oct 29, 2026 · ad-hoc-news.de
- Exelixis (EXEL) vs. BMRN and NBIX: Can CABOMETYX and Pipeline Growth Revive Investor Confidence?Oct 29, 2026 · finance.yahoo.com
- Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?Oct 27, 2026 · finance.yahoo.com
- Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?Oct 26, 2026 · finance.yahoo.com
- Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive DyskinesiaOct 26, 2026 · finance.yahoo.com
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. (NBIX) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in December.